Parameter | All patients | Pirfenidone | Placebo |
---|---|---|---|
(n = 267) | (n = 163) | (n = 104) | |
Gender | Â | Â | Â |
 Male, n (%) | 213 (79.8%) | 132 (81.0%) | 81 (77.9%) |
 Female, n (%) | 54 (20.2%) | 31 (19.0%) | 23 (22.1%) |
Age, year | 64.8 (6.9) | 64.9 (6.7) | 64.7 (7.3) |
 | (n = 267) | (n = 163) | (n = 104) |
BMI | 24.3 (3.0) | 24.1 (2.9) | 24.6 (3.2) |
 | (n = 267) | (n = 163) | (n = 104) |
Smoking | Â | Â | Â |
 Current and former, n (%) | 212 (79.4%) | 129 (79.1%) | 83 (79.8%) |
 Never, n (%) | 55 (20.6%) | 34 (20.9%) | 21 (20.2%) |
Dyspnea scale (modified by Fletcher) | |||
 1, n (%) | 53 (19.9%) | 33 (20.2%) | 20 (19.2%) |
 2, n (%) | 143 (53.6%) | 80 (49.1%) | 63 (60.6%) |
 3, n (%) | 71 (26.6%) | 50 (30.7%) | 21 (20.2%) |
 4 and 5, n (%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
PaO2, Torr | 80.7 (9.6) | 80.5 (9.6) | 81.0 (9.5) |
 | (n = 265) | (n = 161) | (n = 104) |
AaDO2, Torr | 17.7 (10.3) | 17.9 (10.7) | 17.4 (9.7) |
 | (n = 265) | (n = 161) | (n = 104) |
Lowest SpO2 during a 6MET, % | 89.0 (2.2) | 89.0 (2.3) | 89.0 (2.0) |
 | (n = 266) | (n = 162) | (n = 104) |
VC, L | 2.44 (0.67) | 2.41 (0.65) | 2.47 (0.70) |
 | (n = 265) | (n = 161) | (n = 104) |
%VC, % | 77.8 (17.4) | 76.9 (17.4) | 79.1 (17.4) |
 | (n = 265) | (n = 161) | (n = 104) |
%DLCO, % | 53.6 (17.8) | 52.6 (17.6) | 55.2 (18.2) |
 | (n = 264) | (n = 161) | (n = 103) |
Serum SP-D, ng/mL | 238.8 (156.8) | 231.6 (140.8) | 250.1 (179.1) |
 | (n = 267) | (n = 163) | (n = 104) |
Serum SP-A, ng/mL | 93.2 (51.6) | 92.5 (43.8) | 94.3 (62.0) |
 | (n = 267) | (n = 163) | (n = 104) |
Serum KL-6, U/mL | 1317.0 (800.3) | 1318.2 (803.1) | 1315.0 (799.6) |
 | (n = 267) | (n = 163) | (n = 104) |